VENTURE CAPITAL

VENTURE CAPITAL

Perceptive Advisors established our Venture Capital strategy with the launch of our first closed-end fund, Perceptive Xontogeny Venture Fund, LP, in 2018. In 2021, we closed Perceptive Xontogeny Venture Fund II, LP and currently manage over $700 million of capital dedicated to financing early-stage life sciences companies seeking primarily seed and Series A investment, with a select focus on later stage financings. We focus on partnering with founders/entrepreneurs and investing in differentiated technologies that seek to make a significant therapeutic impact on serious disease or improvements in healthcare delivery. The sectors in which we support financings include biotechnology, medtech (medical devices and diagnostics), healthtech, digital health and healthcare tools/services. We prefer to provide active support and a collaborative approach in working with management teams by bringing our operational and strategic experience as Board members to drive successful outcomes.

OUR INVESTMENT APPROACH

Active management via lead or co-lead Series A, and select growth-stage financings, with $10-40 million commitments.
Provide support as a syndicate investor in larger early stage financings
Data driven approach: focus on advancing technologies from preclinical stage through clinical proof-of-concept
Broad-based biotech investing across drug technologies and therapeutic areas
Investing interest across biotechnology and non-therapeutics
Experienced team that brings operational experience to Board of Director roles